Similar articles

Abstract: Objective: To estimate the impact of autologous transfusion on the status of perioperative immune activation in malignant tumor patients. The serum Neopterin and Interleukin-2 (IL-2) were measured. Methods: Sixty patients undergoing elective radical resection for malignant stomach tumor were enrolled in the prospective study and assigned to the following groups: (1) Group A received autologous transfusion. (2) Group H received allogeneic transfusion. The perioperative course (Before induction of anesthesia, after operation and 5 d after operation) of Neopterin and IL-2 was compared. Results: In group A, serum Neopterin was significantly lower than baseline after operation and IL-2 had no significant changes. In group H, both serum Neopterin and IL-2 were significantly lower than baseline after operation and 5 d after operation. Compared with group A, serum Neopterin was significantly lower than baseline after operation and 5 d after operation and IL-2 was significantly lower than baseline 5 d after operation. Conclusion: autologous transfusion decreased the perioperative immune suppression in malignant stomach tumor patients.

[1] Gurlo, T., Huang, W.W., von-Grafenstein, H., 1998. PGE2 inhibits IL-2 and IL-4-dependent proliferation of CTLL-2 and HT2 cells. Cytokine, 10:265-274.

[2] Haupt, W., Riese, J., Mehler, C., 1998. Monocyte function before and after surgical trauma. Dig Surg, 15:102-104.

[3] Heiss, M.M., Merten, K., Allgayer, H., 1997. Influence of autologous blood transfusion on NK and LAK cell activities in cancer surgery. Vox Sang, 73:237-245.

[4] Immanuel, C., Swamy, R., Kannapiran, M., Vijayalakshmi, S., Sundaram, V., Jagannath, K., 1997. Neopterin as a marker for cell-mediated immunity in patients with pulmonary tuberculosis. Int J Tuberc Lung Dis, 1(2):175-180.

[5] Landers, D., Hill, G., Wong, K.C., 1996. Blood transfusion-induced immunomodulation. Anesth Analg, 82:187-204

[6] Liberman, A.C., Refojo, D., Arzt, E., 2003. Cytokine signaling/transcription factor cross-talk in T cell activation and Th1-Th2 differentiation. Arch Immunol Ther Exp (Warsz), 51:351-365.

[7] Lissoni, P., Barni, S., Di-Felice, G., Majorca, F., Fumagalli, L., 1997. Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations. Int J Biol Markers, 12(3):134-136.

[8] Rubin, J.T., 1995. Interleukin-2: its rationale and role in the treatment of patients with cancer. Cancer Treat Res, 80:83-105.

[9] Wachter, H., Fuchs, D., Hausen, A., 1989. Neopterin as marker for activation of cellular immunity: immunological basis and clinical application. Adv Clin Chem, 27:81-91.

[10] Weisbach, V., Wanke, C., Zingsem, J., 1999. Cytokine generation in whole blood, leukocyte-depleted and temporarily warmed red blood cell concentrates. Vox Sang, 76:100-106.